You are here

  • Home
  • Archive
  • Volume 62, Issue 8
  • French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers

Article Text

Article menu
Download PDFPDF
Matters arising
French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers
  1. X Mariette1,
  2. D Salmon2,
  3. Group RATIO3
  1. 1Service de Rhumatologie, Hôpital Bicêtre, Le Kremlin Bicêtre, Hôpital Cochin, Paris, France
  2. 2Service de Médecine Interne, Hôpital Cochin, Paris, France
  3. 3Recherche sur Anti-TNF et Infections Opportunistes
  1. Correspondence to:
    Professor X Mariette;
    xavier.mariette{at}bct.ap-hop-paris.fr

https://doi.org/10.1136/ard.62.8.791

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    In a recent paper in the Annals of the Rheumatic Diseases, Furst et al proposed preliminary consensus guidelines, elaborated during the “Advances in targeted therapies IV” meeting 2002, for diagnosis and treating latent tuberculosis in patients with rheumatoid arthritis (RA) treated with tumour necrosis factor (TNF) blockers.1 Such guidelines cannot be universal and must take into account the prevalence of tuberculosis, the type of immigrants, and the prevalence of vaccination with BCG (bacille Calmette-Guerin) in the country where they are proposed. A multidisciplinary French cooperative group termed RATIO (Recherche sur Anti-TNF et Infections Opportunistes), including specialists in infectious diseases, pneumology, gastroenterology, and rheumatology, recently proposed such guidelines adapted for France,2 which have been validated by the French agency for healthcare product safety (AFSSAPS). These guidelines are intended to help doctors detect and manage tuberculosis in their patients before and after TNF blocker therapy. Moreover, they are now mandatory for all doctors and have to be implemented …

    View Full Text